Efficacy of Olverembatinib in Patients With Chronic-Phase Chronic Myeloid Leukemia With Prior Resistance to Ponatinib or Asciminib and ASXL1 Mutations (SOHO 2026) - Sep 1, 2026 - Abstract #CML-731; Location: LEVEL 3, HALL B3; "These data provide evidence of olverembatinib activity in ponatinib-/asciminib-resistant CP-CML, including patients with ASXL1 mutations. This agent may offer a therapeutic option for patients with relapsed/refractory CP-CML and challenging genotypes after multiple TKIs. ASXL1: ASXL transcriptional regulator 1, BCR:: ABL1: breakpoint cluster region–Abelson 1, TKI: tyrosine kinase inhibitor."
Clinical • Chronic Myeloid Leukemia • Hematological Malignancies • Leukemia • Oncology • ABL1 • ASXL1 • BCR
|
|
Elias Jabbour MD 1; Paul B Koller MD 2; Dennis Kim MD 3; Jorge E Cortes MD 4; Omer Jamy MD 5; Vivian G Oehler MD 6; Maria R Baer MD 7; Anthony M Hunter MD 8; Sudipto Mukehrjee MD,PhD,MPH 9; Huanshan Guo MD 10; Dengkun Xiong 11; Zhiyan Liang PhD 12; Zhihong Yang PhD 12; Hagop Kantarjian MD 1; Yifan Zhai MD PhD 10,11,12
|